ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 689

Patterns of High Disease Activity Status and Outcomes in Systemic Lupus Erythematosus

Alberta Hoi 1, Hieu Nim 2, Rachel Koelmeyer 2, Ying Sun 3, Amy Kao 4, Oliver Guenther 3 and Eric Morand2, 1School of Clinical Sciences, Monash University, Meloburne, Victoria, Australia, 2Monash University, Melbourne, Victoria, Australia, 3Merck Healthcare KGaA, Darmstadt, Germany, 4EMD Serono Research & Development Institute, Inc., Billerica, MA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: damage accrual and High Disease Activity Status, Lupus, prognostic factors

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: SLE – Clinical Poster I: Epidemiology & Pathogenesis

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: High Disease Activity Status (HDAS), defined as ever attainment of SLEDAI-2k of 10 or greater, may be a useful indicator of overall disease severity in systemic lupus erythematosus. The natural history and disease course following episodes of HDAS has not been previously described.

Methods: Using prospectively collected data from the Australian Lupus Registry and Biobank, we examined the patterns and consequences of HDAS. A HDAS episode (until resolution) was defined as the interval from first visit with a recorded SLEDAI -2K≥10, to the time when patient achieved Low Lupus Disease Activity State (LLDAS)1.  Recurrent HDAS was defined as patients who had at least 2 visits with SLEDAI-2k≥10 that were at least 2 months apart. Persistent HDAS was defined as a subset of recurrent HDAS patients in whom SLEDAI-2k was ≥10 at consecutive visits. The associations of these time course patterns with clinical outcomes were analysed.

Results: Data on 286 patients followed for 4.5 +/- 3.3 years were studied. A total of 128 patients had at least one visit that met the criteria for HDAS, accounting for 254 HDAS episodes. The duration of HDAS episodes was variable (median 133 days, IQR 70-245 days), and were significantly longer in patients entering an HDAS episode with SLEDAI-2K > 10 compared to those entering the HDAS episode with SLEDAI-2K = 10 (p=0.003, unpaired heteroscedactic t-test). Accordingly, the likelihood of an HDAS episode lasting > 12 months was 1.89 (95% CI 1.03-3.46, p=0.04) if starting SLEDAI was >10 compared to =10. The number of HDAS episodes increased the odds of damage accrual, with an odds ratio for increased SLICC damage of 4.12 (p< 0.001) if the patient experienced 2 episodes during the observed period (Table 1).

Most HDAS patients had recurrent HDAS (95/128, 74%). Forty-four patients fulfilled the definition of persistent HDAS. Compared to patients who never experienced HDAS, the risk of damage accrual was markedly increased in recurrent HDAS patients, with an OR 3.1 (95% CI 1.82-5.32, p< 0.001). Persistent HDAS patients have the highest risk of damage accrual with an OR 7.13 (95% CI 3.45-15.62, p< 0.001).

Conclusion: HDAS is a clinically relevant SLE disease severity measure, but its disease course can be highly variable. The risk of damage accrual increased progressively according to exposure to HDAS. Patients with persistent HDAS are at the highest risk of damage accrual.

Table 1 – Odds ratio of damage accrual is dependent of the number of HDAS episodes.


Disclosure: A. Hoi, Merck, 2; H. Nim, None; R. Koelmeyer, None; Y. Sun, Merck Healthcare KGaA, 3; A. Kao, EMD Serono, 3; O. Guenther, Merck Healthcare KGaA, 3; E. Morand, AstraZeneca, 2, 5, 8, Bristol Myers Squibb, 2, Eli Lilly, 5, Janssen, 2, 5, Merck Serono, 2, 5, UCB, 2.

To cite this abstract in AMA style:

Hoi A, Nim H, Koelmeyer R, Sun Y, Kao A, Guenther O, Morand E. Patterns of High Disease Activity Status and Outcomes in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/patterns-of-high-disease-activity-status-and-outcomes-in-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patterns-of-high-disease-activity-status-and-outcomes-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology